Cellromax Science Co Net Debt per Share
The Net Debt per Share of Cellromax Science Co (471820.KQ) as of Oct 18, 2026 is 84.43 KRW.
Get this data via API
Financial Data API
Net Debt per Share
84.43KRW
Last updated:
Net Debt per Share of Cellromax Science Co is 2024 84.43 KRW. Net Debt per Share of Cellromax Science Co was 2023 - KRW. It decreases by % lower compared to the previous year.
The Cellromax Science Co Net Debt per Share history
| YEAR | Net Debt per Share | YoY |
|---|---|---|
| 84.43KRW | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cellromax Science Co Stock analysis
What does Cellromax Science Co do? Cellromax Science Co Ltd, headquartered in Yongin, Gyeonggi-Do, South Korea, operates in the health care industry. The company develops and distributes health functional foods, functional cosmetics, and general medicines under brands such as 'Cellromax'. Listed on December 13, 2024, it focuses on products enhancing health and wellness within the Korean market. Cellromax Science Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Cellromax Science Co stock
Net Debt per Share of Cellromax Science Co is 84.43 KRW in 2024.
On Eulerpool you can find the complete historical development of Net Debt per Share Cellromax Science Co since 2006 – with annual values, charts, and detailed analysis.
Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Other — Cellromax Science Co
All Key Metrics — Cellromax Science Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth